Expression of thymidylate synthase in primary colorectal adenocarcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 1, 2006, Pages 37-41

  Lindebjerg, Jan ^a   Nielsen, Jens Nederby ^a   Hoeffding, Lone Damkier ^a   Bisgaard, Claus ^a   Brandslund, Ivan ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

5 fluorouracil; Gene expression; Gene polymorphism; Immunohistochemical staining; Thymidylate synthase

Indexed keywords

DNA; FLUOROURACIL; MESSENGER RNA; RNA; THYMIDYLATE SYNTHASE;

ADENOCARCINOMA; ARTICLE; BLOOD; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA DETERMINATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMORPHISM, GENETIC; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 33645167950     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000154057.41274.6b     Document Type: Article

References (10)

1. Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer. 2001;85:830-927.
2. Miyamoto S, Ochiai A, Narikazy B, et al. Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihadropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int J Oncol. 2001;18:705-713.
3. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res. 2003;6:1322-1327.
4. Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res. 2001;7:4096-4101.
5. Merkelbach-Bruse S, Mathiak HV, Sangueldolce R, et al. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and microsatellite instability phenotype of colorectal cancer. Oncol Rep. 2004;11:839-843.
6. Kawakami K, Omura K, Kanchira E, et al. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 1999;19:3249-3252.
7. Tsuji T, Hidaka S, Sawai T, et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res. 2003;9:3700-3704.
8. Salong D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322-1327.
9. Cascinu S, Aschele C, Barni S, et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res. 1999;5:1996-1999.
10. Edler D, Glimelius B, Hallström M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol. 2002;20:1721-1728.